{"id":"W2598407941","doi":"10.1200/jco.2017.35.4_suppl.tps215","title":"Phase 1 study of ZW25, a bispecific anti-HER2 antibody, in patients with advanced HER2-expressing cancers.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Cancer; Breast cancer; Internal medicine; Oncology; Antibody; Lapatinib; Cancer research; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008234653,0.001718305,0.001105113,0.0004672416,0.0003244727,0.0006518473,0.0007737749,0.001065278,0.00544282],"category_scores_gemma":[0.0004834851,0.0005366072,0.0008229328,0.0002520113,0.0004773762,0.000801611,0.0003698547,0.002013797,0.001247682],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009965061,"about_ca_system_score_gemma":0.001698228,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001106469,"about_ca_topic_score_gemma":0.002701289,"domain_scores_codex":[0.9997908,0.00007579439,0.000008752026,0.00004493123,0.00002694325,0.00005286247],"domain_scores_gemma":[0.9997146,0.00002749474,0.00005841897,0.00001966723,0.00003081107,0.0001489468],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3912901,0.1362687,0.01286664,0.001479291,0.001685285,0.001260438,0.0008419793,0.008236564,0.1928532,0.001042939,0.01762439,0.2345504],"study_design_scores_gemma":[0.2246258,0.7305917,0.01455354,0.00004590511,0.0004397208,0.0009600905,0.0001154977,0.001942741,0.01562496,0.0004445906,0.01061796,0.00003740725],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9828317,0.001659463,0.001361578,0.0004844217,0.00009606375,0.007451234,0.002547673,0.0002167822,0.003351032],"genre_scores_gemma":[0.9741654,0.002020562,0.003259453,0.001223764,0.0001150832,0.006399888,0.004587539,0.00006098868,0.008167417],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00544282,"threshold_uncertainty_score":0.01820809,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.143091718064475,"score_gpt":0.5409719488933747,"score_spread":0.3978802308288997,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}